Active Ingredient(s): Panitumumab
FDA Approved: * September 27, 2006
Pharm Company: * AMGEN
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Vectibix Overview

Panitumumab (INN), formerly ABX-EGF, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans). Panitumumab is manufactured by Amgen and marketed as Vectibix. It was originally developed by Abgenix Inc. In 2014, Amgen and Illumina entered into an agreement to develop a companion diagnostic to accompany panitumumab.[1] Contents 1 Uses 2 FDA Approval 3 Mechanism 4 Pharmacokinetics 5 Adve...

Read more Vectibix Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Vectibix Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 10ml/200mg, 20ml/400mg, 5ml/100mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Vectibix: (3 results)

Sorted by National Drug Code
  • 55513-954 Vectibix 100 mg/5ml Intravenous Solution by Amgen Inc
  • 55513-955 Vectibix 200 mg/10ml Intravenous Solution by Amgen Inc
  • 55513-956 Vectibix 400 mg/20ml Intravenous Solution by Amgen Inc

Other drugs which contain Panitumumab or a similar ingredient: (1 result)